March 16, 2021 -- Medicago and GlaxoSmithKline (GSK) have started phase III of their adjuvanted COVID-19 vaccine candidate clinical trial.
This portion of the trial will enroll 30,000 volunteers from 10 countries, according to the two firms. The vaccine candidate uses coronavirus-like-particle technology; two doses of 3.75 µg are administered three weeks apart. The drug has been granted "fast track" designation by the U.S. Food and Drug Administration (FDA).
Medicago has also begun a feasibility study of a vaccine candidate for emerging COVID-19 variants, it said.